These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8725714)

  • 1. Predicting daily maintenance dose of fluindione, an oral anticoagulant drug.
    Cazaux V; Gauthier B; Elias A; Lefebvre D; Tredez J; Nguyen F; Cambus JP; Boneu B; Boccalon H
    Thromb Haemost; 1996 May; 75(5):731-3. PubMed ID: 8725714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.
    Siguret V; Gouin I; Debray M; Perret-Guillaume C; Boddaert J; Mahé I; Donval V; Seux ML; Romain-Pilotaz M; Gisselbrecht M; Verny M; Pautas E
    Am J Med; 2005 Feb; 118(2):137-42. PubMed ID: 15694897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of regimen fluindione needed for anticoagulation in the elderly].
    Lechowski L; Teillet L; Harboun M; Tortrat D; Forette B
    Rev Med Interne; 2002 Dec; 23(12):1022-6. PubMed ID: 12504240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin.
    Crowther MA; Donovan D; Harrison L; McGinnis J; Ginsberg J
    Thromb Haemost; 1998 Jun; 79(6):1116-8. PubMed ID: 9657434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients.
    Mentré F; Pousset F; Comets E; Plaud B; Diquet B; Montalescot G; Ankri A; Mallet A; Lechat P
    Clin Pharmacol Ther; 1998 Jan; 63(1):64-78. PubMed ID: 9465843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Divisibility of warfarin and fluindione tablets tested in elderly patients and their family circle].
    Pautas E; Despres J; Peyron I; Golmard JL; Grange J; Koenig N; Gouronnec A; Mitha N; Siguret V; Gouin-Thibault I
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):171-7. PubMed ID: 21690025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between maintenance dosages of fluindione (Préviscan) and warfarin (Coumadin) for patients 70 years and older].
    Pautas É; Peyron I; Gouin-Thibault I; Gouronnec A; Monti A; Bouhadiba S; Badie C; Golmard JL; Siguret V
    Rev Med Interne; 2015 Jan; 36(1):7-9. PubMed ID: 24373728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective and prospective analyses of the treatment of overanticoagulated patients.
    Duong TM; Plowman BK; Morreale AP; Janetzky K
    Pharmacotherapy; 1998; 18(6):1264-70. PubMed ID: 9855325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
    Yasaka M; Sakata T; Naritomi H; Minematsu K
    Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats.
    Cao YG; Liu XQ; Chen YC; Hao K; Wang GJ
    Eur J Pharm Sci; 2007 Feb; 30(2):175-80. PubMed ID: 17169538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal initial dose adjustment of warfarin in orthopedic patients.
    Lenzini PA; Grice GR; Milligan PE; Gatchel SK; Deych E; Eby CS; Burnett RS; Clohisy JC; Barrack RL; Gage BF
    Ann Pharmacother; 2007 Nov; 41(11):1798-804. PubMed ID: 17911206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting warfarin maintenance dosage based on initial response.
    Miller DR; Brown MA
    Am J Hosp Pharm; 1979 Oct; 36(10):1351-5. PubMed ID: 507078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin induction at 5 mg daily is safe with a low risk of anticoagulant overdose: results of an audit of patients with deep vein thrombosis commencing warfarin.
    Harper P; Monahan K; Baker B
    Intern Med J; 2005 Dec; 35(12):717-20. PubMed ID: 16313547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling INR data to predict maintenance fluindione dosage.
    Comets E; Mentré F; Pousset F; Diquet B; Montalescot G; Ankri A; Mallet A; Lechat P
    Ther Drug Monit; 1998 Dec; 20(6):631-9. PubMed ID: 9853979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose vitamin K to augment anticoagulation control.
    Reese AM; Farnett LE; Lyons RM; Patel B; Morgan L; Bussey HI
    Pharmacotherapy; 2005 Dec; 25(12):1746-51. PubMed ID: 16305294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation.
    Watzke HH; Forberg E; Svolba G; Jimenez-Boj E; Krinninger B
    Thromb Haemost; 2000 May; 83(5):661-5. PubMed ID: 10823258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.